Skip to main content

Intracavernosal Injection Agents

Intracavernosal injection (ICI) agents span four urologic applications: (1) therapeutic ICI for erectile dysfunction (AUA second-line); (2) intralesional injection for Peyronie's disease (CCH is the only FDA-approved intralesional agent); (3) diagnostic ICI to induce a pharmacologic erection for penile duplex Doppler ultrasound; and (4) emergency intracavernosal sympathomimetic administration for ischemic priapism and prolonged post-ICI erection. ICI was the first pharmacologic treatment for ED — introduced by Virag (papaverine) and Brindley (phenoxybenzamine) in 1982 — and remains a highly effective tool in the PDE5-inhibitor era, with clinical efficacy rates of 54–100% across agents and populations.[1][2][3]

For related classes, see PDE5 inhibitors, Intraurethral alprostadil, Peyronie's disease agents, and Priapism management.

Agents — mechanisms and FDA status​

AgentMechanismFDA statusTypical urologic role
Alprostadil (PGE1) — Caverject / Edex↑ cAMP via PGE1 receptor → trabecular smooth-muscle relaxation + cavernosal artery dilation + presynaptic NE inhibitionFDA-approved for ICI and as diagnostic adjunct[4][5]ED monotherapy; diagnostic PDUS; penile rehab
PapaverineNonspecific PDE inhibitor → ↑ cAMP and ↑ cGMPOff-labelComponent of TriMix / QuadMix; highest fibrosis and priapism risk as monotherapy[1]
Phentolamineα1/α2 antagonist → blocks sympathetic-mediated detumescenceOff-labelCombination component — weak as monotherapy; reduces reflex tachycardia when added
Aviptadil (VIP) + phentolamine (Invicorp)VIP increases cAMP; phentolamine sympatholysisApproved in select regions (UK, EU)Refractory ED after alprostadil failure; lowest priapism signal (0.3%)[6]
AtropineMuscarinic antagonist → blocks parasympathetic detumescenceOff-labelQuadMix component only
Collagenase clostridium histolyticum (Xiaflex / CCH)Bacterial collagenase that cleaves types I and III collagenFDA-approved for Peyronie's plaque (REMS program)[7]Intralesional — not intracorporal
VerapamilCalcium channel blocker; inhibits ECM synthesis, upregulates collagenase, modulates TGF-βOff-labelIntralesional Peyronie's (minimal benefit in RCT)
Interferon α-2bAntifibrotic cytokineOff-labelIntralesional Peyronie's
PhenylephrinePure α1-agonistOff-label (for priapism)Ischemic priapism + prolonged post-ICI erection first-line

ICI for erectile dysfunction — AUA second-line​

AUA ED guideline 2018 — Moderate Recommendation, Grade C: ICI is recommended for men who have contraindications to PDE5 inhibitors, prefer not to take oral medication, or find PDE5 inhibitors inadequate or ineffective. An in-office injection test must be performed before initiating self-injection therapy (Clinical Principle).[1]

Alprostadil monotherapy​

Only FDA-approved ICI agent in the US. Induces erection within 5–10 min independent of sexual stimulation via PGE1-receptor activation and cAMP elevation, with additional attenuation of presynaptic norepinephrine release.[4]

FDA-label dosing:[4][5]

EtiologyStarting doseMaximum
Vasculogenic / psychogenic / mixed2.5 µg60 µg
Pure neurogenic (SCI, post-pelvic-surgery neuropraxia)1.25 µg60 µg
  • Titrate upward in-office
  • No more than 3 doses per week, with ≥24 h between doses
  • Penile pain reported by 29–35% of patients initially (decreases over time — 41% in the first 2 months → 3% by months 21–24)
  • Prolonged erection (>4 h) occurs in ~4% in clinical trials[4][5]

Combination formulations — the workhorse of real-world ICI practice​

The rationale is synergy — different mechanisms at lower individual doses reduce both pain (alprostadil-dose-dependent) and fibrosis (papaverine-dose-dependent).[8][9]

FormulationComponentsRoleTypical response
BiMixPapaverine + phentolamineOriginal combination; Level 2 evidenceLowest satisfaction among combinations (~53%)[1][9]
TriMixAlprostadil + papaverine + phentolamineMost widely used combination~90% success — the highest of any ICI[9][10]
QuadMixTriMix + atropineSalvage after TriMix failureLimited case-series data[1]
Aviptadil + phentolamine (Invicorp)VIP + α-blockerRefractory ED, particularly post-alprostadil-pain dropouts59% overall; 76% in patients switched for alprostadil pain; 36% in maximal-dose alprostadil failure[6]

Typical TriMix compounding concentrations vary by pharmacy: alprostadil 10–20 µg/mL + papaverine 30 mg/mL + phentolamine 1–2 mg/mL. In the Coombs tertiary-center series (n = 1,412), 89% of TriMix users achieved intercourse-capable erections.[11]

In-office titration and training​

  • 28–30-gauge needle inserted laterally into the corpus cavernosum at the proximal or mid-shaft
  • Avoid the dorsal neurovascular bundle and the urethra
  • Alternate injection site between sides and locations to minimize fibrosis risk
  • Start at the lowest effective dose; titrate upward across sessions
  • Train the patient (or partner) during the in-office session; review management of prolonged erection and when to present to the ED[1][12]

Long-term outcomes and discontinuation​

Despite high efficacy, discontinuation is the dominant clinical challenge:

  • Duncan 2019 global review — early discontinuation rates up to 38%, highest in the first 3–6 months; injection-related anxiety in ~65% that can persist for 4 months[3]
  • Gupta 1997 (n = 1,089) — overall attrition 37.6% (27.5% for PGE1 users); >50% of dropouts in the first 2 months; attrition <10% thereafter across 2 years[13]
  • Coombs 2012 (n = 1,412) — significant discontinuation by year 3; many post-prostatectomy patients discontinue because natural or PDE5i-assisted erections recover[11]
  • Bearelly 2020 long-term users (mean 8.4 y) — rigidity improved 41.1% → 89.6%; priapism 7.1%, penile curvature 10%[14]
  • Vardi 2000 — papaverine/phentolamine dropout 2× that of TriMix / PGE1; injection volumes >0.5 mL predicted dropout[15]

Predictors of ICI failure: pelvic radiation, diabetes mellitus, severe venous leak.[11][13]

Adverse effects​

  • Penile pain — most common with alprostadil (29–35%); decreases over time; less common with TriMix and aviptadil/phentolamine[4][6]
  • Prolonged erection / priapism — 0.5–4% depending on agent. Papaverine-containing combinations have the highest priapism signal because they counter normal detumescence pathways; aviptadil/phentolamine has the lowest (0.3%)[4][6][11]
  • Penile fibrosis — 3–7.8% overall with alprostadil up to 18 months; highest with papaverine monotherapy. Examine the penis periodically; discontinue if angulation or cavernosal fibrosis develops[4]
  • Hematoma / ecchymosis — increased risk on anticoagulants[4]
  • Hypotension — particularly with cavernosal venous leak (systemic absorption)[4]

Intralesional injection for Peyronie's disease​

Collagenase clostridium histolyticum (CCH / Xiaflex) — FDA-approved​

Indication: adult men with a palpable plaque and curvature of ≥30° at the start of therapy.[7] Per the AUA Peyronie's guideline 2015, CCH may be administered with concurrent modeling in patients with stable disease, curvature >30° and <90°, intact erectile function with or without PDE5i use, and in the absence of contraindications.[16]

Protocol:[7]

  • 0.58 mg per injection, given as 2 injections 1–3 days apart per cycle
  • Penile modeling performed 1–3 days after the second injection
  • Up to 4 treatment cycles at ~6-week intervals (maximum 8 injections, 4 modeling procedures)

Efficacy: IMPRESS I/II — mean curvature reduction 17° (CCH) vs 9.3° (placebo), absolute difference 7.7°.[16] Russo 2019 network meta-analysis ranked CCH and interferon α-2b as the best intralesional options for curvature reduction.[17]

Boxed Warning — corporal rupture (penile fracture): 0.5% directly reported; an additional 0.9% had findings where rupture could not be excluded. Severe penile hematoma in 3.7%. Most common AEs (≥25%): penile hematoma 65.5%, swelling 55.0%, pain 45.4%. Available only through the XIAFLEX REMS Program.[7]

Verapamil​

Calcium channel blocker — inhibits ECM synthesis, increases collagenase activity, modifies TGF-β.[18] AUA guideline notes an RCT of electromotive verapamil showed minimal benefit vs placebo; the Russo 2019 network meta placed verapamil behind CCH and IFN α-2b on curvature outcomes.[16][17] Evidence is limited to single-arm and case-control studies.[19]

Interferon α-2b​

Curvature reduction of 12–13.5°, plaque-size and pain improvement in controlled studies; Russo 2019 ranked it alongside CCH for curvature outcomes.[17][20] Flu-like symptoms limit tolerance; not FDA-approved for PD.

Acute-phase intralesional therapy​

Manfredi 2025 systematic review (20 studies, n = 1,291) of calcium channel blockers, hyaluronic acid, CCH, IFN, and corticosteroids for acute-phase PD — most studies showed curvature and pain improvements with mild local AEs, but overall evidence quality is low.[21]

See Peyronie's disease agents and the clinical Peyronie's disease article.

Diagnostic ICI for penile duplex Doppler ultrasound​

Diagnostic ICI induces pharmacologic erection to assess arterial inflow (peak systolic velocity normal >30 cm/s) and veno-occlusive function (end-diastolic velocity normal <5 cm/s).[22][23]

AgentDiagnostic doseNotes
Alprostadil10–20 µgMost commonly used; FDA-approved as diagnostic adjunct[4]
TriMixInstitution-specificPreferred at many centers — more complete cavernosal relaxation, improving diagnostic accuracy[22][23]
Papaverine12.5 mgHistorical; good arterial dilation but less useful for veno-occlusive assessment[24]

Redose if initial injection does not produce full rigidity — PDUS accuracy depends entirely on complete cavernosal smooth-muscle relaxation.[22] Evaluate for detumescence after the study; persistent penetration-rigidity erection is treated with intracavernosal phenylephrine.[22]

Priapism — intracavernosal phenylephrine​

Intracavernosal phenylephrine is the first-line pharmacologic treatment for ischemic priapism and for prolonged post-ICI erection.[25][26][27]

AUA/SMSNA priapism guideline 2022:[25]

  • Prolonged erection ≤4 h after ICI: intracavernosal phenylephrine as initial treatment (Expert Opinion)
  • Erection >4 h: follow the acute ischemic priapism algorithm — aspiration + intracavernosal phenylephrine ± saline irrigation

Dosing: phenylephrine 100–500 µg (diluted in normal saline) every 3–5 min, with blood pressure and heart rate monitoring. Use 100 µg in children and in patients with cardiovascular disease.[26]

Scarberry 2022 retrospective (n = 123 acute ischemic priapism) — phenylephrine achieved nonoperative detumescence in 63.9%, with shorter priapism duration predicting resolution (8.8 vs 57.3 h; p < 0.05).[28]

Why phenylephrine over other sympathomimetics? Epinephrine and etilefrine have been used historically; phenylephrine is preferred for its pure α1-agonist activity and minimal β effect — fewer cardiovascular AEs (less tachycardia, lower arrhythmia risk).[26]

See Priapism management.

ICI in post-prostatectomy penile rehabilitation​

ICI is a cornerstone of multimodal rehabilitation after radical prostatectomy, typically layered onto scheduled PDE5i and vacuum erection-device (VED) use.[29][30]

  • Nauta 2025 academic rehab program — tadalafil 20 mg every other day + Caverject 5 µg weekly + daily VED achieved EF recovery up to 80% at 2 years[30]
  • Teloken 2009 ISSM survey — 75% of practitioners use ICI as part of post-RP rehabilitation; 54% commence immediately after catheter removal[31]
  • Miranda 2021 3-arm RCT (placebo + on-demand sildenafil vs nightly sildenafil vs nightly sildenafil + twice-weekly ICI) — underpowered; no statistical difference among groups highlighted the difficulty of running adequately powered rehab RCTs[32]

ICI is particularly valuable in the early post-RP window — during neuropraxia, when PDE5 inhibitors may fail because NO signaling requires intact cavernosal nerve input, whereas ICI agents act downstream of the nerve, bypassing the defect.[33] See PDE5 inhibitors for the companion oral-therapy framework.

Note — MUSE transurethral alprostadil​

Not intracavernosal, but the adjacent delivery route. The Medicated Urethral System for Erection (MUSE) delivers alprostadil as an intraurethral pellet absorbed through urethral mucosa into the corpus cavernosum via the spongiosum. Systematic review of 3 RCTs (n = 1,828) showed intercourse success 65% vs 18% placebo (p < 0.001). Success rates (43–69%) are lower than ICI.[9][10] Adverse effects: penile and urethral pain/burning, hypotension, syncope, rare priapism. Covered in detail in Intraurethral alprostadil.

Evidence Summary​

ApplicationAgent(s)FDA statusEfficacyKey source
ED — monotherapyAlprostadilApproved~70%Caverject/Edex labels[4][5]
ED — combinationTriMixCompounded (off-label)~90%Coombs 2012[11]; Porst 2013[9]
ED — refractoryAviptadil + phentolamineApproved in select regions59% overall; 76% after alprostadil-pain switchAl-Mitwalli 2025[6]
Peyronie's — intralesionalCCH (Xiaflex)Approved (REMS)17° curvature reductionIMPRESS / AUA 2015[7][16]
Peyronie's network comparisonCCH + IFN α-2bMixedBest outcomesRusso 2019 network MA[17]
Diagnostic PDUSAlprostadil / TriMix / papaverineAlprostadil approved as adjunctInduces pharmacologic erectionSikka 2013 SOP[23]
Priapism / post-ICI prolonged erectionPhenylephrineOff-label64% nonoperative resolutionAUA/SMSNA 2022[25]; Scarberry 2022[28]
Post-RP rehabilitationAlprostadil low-dose; TriMixOff-labelUp to 80% at 2 y (multimodal)Nauta 2025[30]

Clinical Positioning​

  • ICI is AUA second-line ED therapy for men who fail, can't tolerate, or can't take PDE5 inhibitors. An in-office titration is required before self-injection — it is the single most important safety and adherence step.[1]
  • TriMix is the workhorse. ~90% response, lower pain than alprostadil monotherapy, and lower priapism than papaverine alone. Alprostadil monotherapy is reasonable but pain drives dropout.[9][11]
  • Aviptadil + phentolamine (Invicorp) is the best-supported rescue for alprostadil-pain switchers where it is available.[6]
  • Discontinuation is the dominant clinical problem, not efficacy. >50% of dropouts occur in the first 2 months — front-load counseling, partner involvement, and follow-up contact.[3][13]
  • Rotate injection sites and keep injection volume ≤0.5 mL to reduce fibrosis and dropout.[4][15]
  • CCH is the only FDA-approved intralesional PD agent. Stable disease, curvature 30–90°, intact EF, REMS program, up to 4 cycles, modeling after each cycle. Boxed warning for corporal rupture is load-bearing — warn patients explicitly.[7][16]
  • For PDUS, TriMix achieves more complete cavernosal relaxation than alprostadil alone and improves diagnostic accuracy. Redose if rigidity is incomplete; always evaluate for detumescence at the end of the study.[22][23]
  • Intracavernosal phenylephrine 100–500 µg every 3–5 min is the first-line for ischemic priapism and post-ICI prolonged erection; dose down to 100 µg in children and cardiac patients.[25][26]
  • In post-RP rehabilitation, ICI bypasses the neuropraxic defect that limits PDE5i efficacy in the early window. Layer low-dose Caverject weekly onto scheduled PDE5i and VED for the first 6–12 months.[30][33]
  • Anticoagulation is not an absolute contraindication but raises hematoma risk — counsel and consider dose holding for first-injection titration.[4]

See Also​

References​

1. Burnett AL, Nehra A, Breau RH, et al. "Erectile dysfunction: AUA guideline." J Urol. 2018;200(3):633–641. doi:10.1016/j.juro.2018.05.004

2. Elena BW, Zachary M, Haritha P, Graham BA, Wayne HJG. "Current status of intracavernosal injection therapy in erectile dysfunction." Expert Opin Pharmacother. 2023;24(8):925–933. doi:10.1080/14656566.2023.2204189

3. Duncan C, Omran GJ, Teh J, et al. "Erectile dysfunction: a global review of intracavernosal injectables." World J Urol. 2019;37(6):1007–1014. doi:10.1007/s00345-019-02727-5

4. US Food and Drug Administration. Caverject (alprostadil) — prescribing information. Updated 2024-05-13.

5. US Food and Drug Administration. Edex (alprostadil) — prescribing information. Updated 2024-03-27.

6. Al-Mitwalli A, Holden F, Di Giovanni A, et al. "Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction." J Sex Med. 2025;22(5):726–730. doi:10.1093/jsxmed/qdaf067

7. US Food and Drug Administration. XIAFLEX (collagenase clostridium histolyticum) — prescribing information. Updated 2024-04-05.

8. McVary KT. "Erectile dysfunction." N Engl J Med. 2007;357(24):2472–2481. doi:10.1056/NEJMcp067261

9. Porst H, Burnett A, Brock G, et al. "SOP conservative (medical and mechanical) treatment of erectile dysfunction." J Sex Med. 2013;10(1):130–171. doi:10.1111/jsm.12023

10. Chao R, Clowers DE. "Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction." Arch Phys Med Rehabil. 1994;75(3):276–278. doi:10.1016/0003-9993(94)90028-0

11. Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. "A review of outcomes of an intracavernosal injection therapy programme." BJU Int. 2012;110(11):1787–1791. doi:10.1111/j.1464-410X.2012.11080.x

12. Shamloul R, Ghanem H. "Erectile dysfunction." Lancet. 2013;381(9861):153–165. doi:10.1016/S0140-6736(12)60520-0

13. Gupta R, Kirschen J, Barrow RC, Eid JF. "Predictors of success and risk factors for attrition in the use of intracavernous injection." J Urol. 1997;157(5):1681–1686.

14. Bearelly P, Phillips EA, Pan S, et al. "Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction." Int J Impot Res. 2020;32(3):345–351. doi:10.1038/s41443-019-0186-z

15. Vardi Y, Sprecher E, Gruenwald I. "Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters." J Urol. 2000;163(2):467–470.

16. Nehra A, Alterowitz R, Culkin DJ, et al. "Peyronie's disease: AUA guideline." J Urol. 2015;194(3):745–753. doi:10.1016/j.juro.2015.05.098

17. Russo GI, Cacciamani G, Cocci A, et al. "Comparative effectiveness of intralesional therapy for Peyronie's disease in controlled clinical studies: a systematic review and network meta-analysis." J Sex Med. 2019;16(2):289–299. doi:10.1016/j.jsxm.2018.12.011

18. Rosenberg JE, Ergun O, Hwang EC, et al. "Non-surgical therapies for Peyronie's disease." Cochrane Database Syst Rev. 2023;7:CD012206. doi:10.1002/14651858.CD012206.pub2

19. Russo GI, Milenkovic U, Hellstrom W, et al. "Clinical efficacy of injection and mechanical therapy for Peyronie's disease: a systematic review of the literature." Eur Urol. 2018;74(6):767–781. doi:10.1016/j.eururo.2018.07.005

20. Hayat S, Brunckhorst O, Alnajjar HM, et al. "A systematic review of non-surgical management in Peyronie's disease." Int J Impot Res. 2023;35(6):523–532. doi:10.1038/s41443-022-00633-w

21. Manfredi C, Russo GI, Capogrosso P, et al. "Injection therapy in the acute phase of Peyronie's disease: a systematic review of current evidence." J Sex Med. 2025;22(5):799–812. doi:10.1093/jsxmed/qdaf044

22. Flores JM, West M, Mulhall JP. "Efficient use of penile Doppler ultrasound for investigating men with erectile dysfunction." J Sex Med. 2024;21(8):734–739. doi:10.1093/jsxmed/qdae070

23. Sikka SC, Hellstrom WJ, Brock G, Morales AM. "Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound." J Sex Med. 2013;10(1):120–129. doi:10.1111/j.1743-6109.2012.02825.x

24. Meuleman EJ, Bemelmans BL, Doesburg WH, et al. "Penile pharmacological duplex ultrasonography: a dose-effect study comparing papaverine, papaverine/phentolamine and prostaglandin E1." J Urol. 1992;148(1):63–66. doi:10.1016/s0022-5347(17)36511-4

25. Bivalacqua TJ, Allen BK, Brock GB, et al. "The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA/SMSNA guideline." J Urol. 2022;208(1):43–52. doi:10.1097/JU.0000000000002767

26. Graham BA, Wael A, Jack C, Rohan MA, Wayne HJG. "An overview of emergency pharmacotherapy for priapism." Expert Opin Pharmacother. 2022;23(12):1371–1380. doi:10.1080/14656566.2022.2099271

27. Pang KH, Alnajjar HM, Lal A, Muneer A. "An update on mechanisms and treatment options for priapism." Nat Rev Urol. 2025. doi:10.1038/s41585-025-01069-9

28. Scarberry K, Deebel NA, Dutta R, Matz E, Terlecki RP. "Safety and efficacy of phenylephrine administration for the treatment of ischemic priapism: an opportunity for quality improvement in periprocedural safety assessment." Urology. 2022;169:115–119. doi:10.1016/j.urology.2022.08.011

29. Philippou YA, Jung JH, Steggall MJ, et al. "Penile rehabilitation for postprostatectomy erectile dysfunction." Cochrane Database Syst Rev. 2018;10:CD012414. doi:10.1002/14651858.CD012414.pub2

30. Nauta MD, Falagario UG, Ricapito A, et al. "Sexual function recovery following open and robotic radical prostatectomy: results of an academic penile rehabilitation program." Asian J Androl. 2025. doi:10.4103/aja202525

31. Teloken P, Mesquita G, Montorsi F, Mulhall J. "Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the International Society for Sexual Medicine practitioners." J Sex Med. 2009;6(7):2032–2038. doi:10.1111/j.1743-6109.2009.01269.x

32. Miranda EP, Benfante N, Kunzel B, Nelson CJ, Mulhall JP. "A randomized, controlled, 3-arm trial of pharmacological penile rehabilitation in the preservation of erectile function after radical prostatectomy." J Sex Med. 2021;18(2):423–429. doi:10.1016/j.jsxm.2020.10.022

33. Lima TFN, Bitran J, Frech FS, Ramasamy R. "Prevalence of post-prostatectomy erectile dysfunction and a review of the recommended therapeutic modalities." Int J Impot Res. 2021;33(4):401–409. doi:10.1038/s41443-020-00374-8